Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolong ejaculation.
Popular Articles

Government Targets Interfere With The Battle Against Superbugs, Says British Medical Association
The war on healthcare associated infections (HCAIs), or so-called "superbugs", will never be won unless long-term strategies are introduced to radically reduce their prevalence, says a BMA report launched recently.
generic viagra
Report Finds Racial Disparities In Prescription Drug Access, Use, Regimen Adherence
"Origins and Strategies for Addressing Ethnic and Racial Disparities in Pharmaceutical Therapy: The Health-Care System, the Provider, and the Patient," National Minority Quality Forum: The report -- by Richard Levy, a health care consultant and former vice president of the National Pharmaceutical Council; Robert Like, professor and director of the Center for Healthy Families and Cultural Diversity of the UMDNJ-Robert Wood Johnson Medical School; and Harry Shabsin, a private-practice psychologist -- looks at how appropriate medications for a variety of diseases often are under-prescribed, over-prescribed, or mis-prescribed among minorities. The report looks at disparities in treatment of minority patients with cardiovascular disease, asthma, psychiatric illness, pain and other conditions and finds disparities in access to medications through insurance programs, in the prescribing of medications and in adherence to medication regimens. The report offers ways to improve prescribing and use of medications among diverse communities (National Minority Quality Forum release, 5/12).
News of the day
Men And Women See Things Differently
Sex differences in how the brain processes visual information could be a legacy of our hunter-gather past. This is the conclusion of a paper published online today, 30th July 2009, in the British Journal of Psychology.
Diagnostics

Affymax Announces Data Monitoring Committee Review Of Phase 3 Hematide Program

Affymax, Inc. (Nasdaq:AFFY) announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide™, has completed another review and has informed the company that the cumulative safety data generated thus far from the EMERALD and PEARL Phase 3 trials support continuation of the studies. In the Phase 3 program, Hematide is being evaluated to treat anemia in chronic renal failure patients on dialysis and not on dialysis. The Phase 3 program, which consists of four trials, was initiated in October 2007. Affymax announced that enrollment was complete in all four Phase 3 trials in November 2008 and reiterated its expectation for a NDA submission in 2010. About Hematide Hematide is a novel synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent (ESA). Affymax and Takeda Pharmaceutical Company Limited are collaborating on the development of Hematide and plan to co-commercialize the product in the United States. The product, upon approval, will be commercialized in the European Union by Takeda. Affymax is conducting Phase 3 clinical trials which may support a NDA submission for Hematide to treat anemia associated with chronic renal failure. About Anemia in Chronic Renal Failure (CRF) Anemia in CRF affects many individuals with Chronic Kidney Disease (CKD). According to the National Kidney Foundation, 20 million Americans - 1 in 9 U.S. adults - have CKD. Anemia develops in the early stages of CKD and worsens as patients progress towards total kidney failure and need a dialysis machine to eliminate waste and water from their blood. In severe or prolonged cases of anemia, the lack of oxygen in the blood can cause serious and sometimes fatal damage to the heart and other organs. Benefits of anemia correction in patients with CKD include decreased morbidity, hospitalization, and mortality.1 1. http://www.anemia.org/pdf/mon_Anemia_and_CKD.pdf Affymax, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009